ALC-0315 [2036272-55-4]
Cat# T9277-100mg
Size : 100mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
ALC-0315
Copy Product Info
ALC-0315 is an ionizable cationic lipid that serves as a core component of lipid nanoparticle (LNP) delivery systems for mRNA vaccines, responsible for efficiently encapsulating, protecting, and delivering nucleic acids into cells. Lipid nanoparticles have already been used in research on mRNA (COVID-19) vaccines.
Cas No. 2036272-55-4
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.66%
Color:Transparent
COA HNMR MS
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ALC-0315 is an ionizable cationic lipid that serves as a core component of lipid nanoparticle (LNP) delivery systems for mRNA vaccines, responsible for efficiently encapsulating, protecting, and delivering nucleic acids into cells. Lipid nanoparticles have already been used in research on mRNA (COVID-19) vaccines. |
| In vitro | Methods: Primary HSCs were isolated from mouse livers. After 2 hours of plating, cell lysates were collected for RNA extraction. One week after LNP-siRNA injection, HSCs were isolated, and target gene mRNA levels were detected by qPCR. Results: ALC-0315 LNP achieved stronger gene silencing in HSCs compared to MC3 LNP. [1] |
| In vivo | Methods: LNPs encapsulating different siRNAs (targeting FVII [hepatocytes] or ADAMTS13 [HSCs], or control siLuc) were administered via tail vein injection at doses of 1 mg/kg siRNA (standard silencing dose) or 5 mg/kg siRNA (high dose for toxicity assessment). Animals were euthanized 1 week after dosing, and blood and liver tissue were collected for analysis. Results: Hepatocyte silencing (FVII): At a dose of 1 mg/kg, the knockdown effect of ALC-0315 LNP on plasma FVII protein levels was approximately twice that of MC3 LNP. Hepatic stellate cell silencing (ADAMTS13): at a dose of 1 mg/kg, the inhibitory effect of ALC-0315 LNP on plasma ADAMTS13 activity was approximately 10 times that of MC3 LNP. [1] Methods: Female BALB/c mice were selected and received intramuscular (IM) injections of ALC0315-DNA, ALC0315-RNA, or an empty LNP control into both tibialis anterior muscles. Imaging was performed at 6 h, 24 h, 48 h, 72 h, 7 d, 14 d, 21 d, and 28 d. Results: The signal intensity of RNA-LNP was significantly higher than that of DNA-LNP. The expression duration of ALC0315-DNA was >28 days, while that of ALC0315-RNA was 21 days.[2] |
| Molecular Weight | 766.27 |
| Formula | C48H95NO5 |
| Cas No. | 2036272-55-4 |
| Smiles | CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCO)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC |
| Relative Density. | 0.919 g/cm3 (Predicted) |
| Storage | Keep away from direct sunlight Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (130.5 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (5.22 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||